RESUMEN
Pathogen inactivation of platelet concentrates reduces the risk for blood-borne infections. However, its effect on platelet function and hemostatic efficacy of transfusion is unclear. We conducted a randomized noninferiority trial comparing the efficacy of pathogen-inactivated platelets using riboflavin and UV B illumination technology (intervention) compared with standard plasma-stored platelets (control) for the prevention of bleeding in patients with hematologic malignancies and thrombocytopenia. The primary outcome parameter was the proportion of transfusion-treatment periods in which the patient had grade 2 or higher bleeding, as defined by World Health Organization criteria. Between November 2010 and April 2016, 469 unique patients were randomized to 567 transfusion-treatment periods (283 in the control arm, 284 in the intervention arm). There was a 3% absolute difference in grade 2 or higher bleeding in the intention-to-treat analysis: 51% of the transfusion-treatment periods in the control arm and 54% in the intervention arm (95% confidence interval [CI], -6 to 11; P = .012 for noninferiority). However, in the per-protocol analysis, the difference in grade 2 or higher bleeding was 8%: 44% in the control arm and 52% in the intervention arm (95% CI -2 to 18; P = .19 for noninferiority). Transfusion increment parameters were â¼50% lower in the intervention arm. There was no difference in the proportion of patients developing HLA class I alloantibodies. In conclusion, the noninferiority criterion for pathogen-inactivated platelets was met in the intention-to-treat analysis. This finding was not demonstrated in the per-protocol analysis. This trial was registered at The Netherlands National Trial Registry as #NTR2106 and at www.clinicaltrials.gov as #NCT02783313.
Asunto(s)
Plaquetas/metabolismo , Hemostasis , Transfusión de Plaquetas , Coagulación Sanguínea , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Estudios Multicéntricos como Asunto , Evaluación del Resultado de la Atención al Paciente , Pruebas de Función Plaquetaria , Transfusión de Plaquetas/efectos adversos , Transfusión de Plaquetas/métodos , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND: Patient blood management combines the use of several transfusion alternatives. Integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices on allogeneic erythrocyte use was evaluated using a restrictive transfusion threshold. METHODS: In a factorial design, adult elective hip- and knee-surgery patients with hemoglobin levels 10 to 13 g/dl (n = 683) were randomized for erythropoietin or not, and subsequently for autologous reinfusion by cell saver or postoperative drain reinfusion devices or for no blood salvage device. Primary outcomes were mean allogeneic intra- and postoperative erythrocyte use and proportion of transfused patients (transfusion rate). Secondary outcome was cost-effectiveness. RESULTS: With erythropoietin (n = 339), mean erythrocyte use was 0.50 units (U)/patient and transfusion rate 16% while without (n = 344), these were 0.71 U/patient and 26%, respectively. Consequently, erythropoietin resulted in a nonsignificant 29% mean erythrocyte reduction (ratio, 0.71; 95% CI, 0.42 to 1.13) and 50% reduction of transfused patients (odds ratio, 0.5; 95% CI, 0.35 to 0.75). Erythropoietin increased costs by 785 per patient (95% CI, 262 to 1,309), that is, 7,300 per avoided transfusion (95% CI, 1,900 to 24,000). With autologous reinfusion, mean erythrocyte use was 0.65 U/patient and transfusion rate was 19% with erythropoietin (n = 214) and 0.76 U/patient and 29% without (n = 206). Compared with controls, autologous blood reinfusion did not result in erythrocyte reduction and increased costs by 537 per patient (95% CI, 45 to 1,030). CONCLUSIONS: In hip- and knee-replacement patients (hemoglobin level, 10 to 13 g/dl), even with a restrictive transfusion trigger, erythropoietin significantly avoids transfusion, however, at unacceptably high costs. Autologous blood salvage devices were not effective.
Asunto(s)
Artroplastia de Reemplazo de Cadera/métodos , Artroplastia de Reemplazo de Rodilla/métodos , Transfusión de Sangre Autóloga/métodos , Procedimientos Quirúrgicos Electivos/métodos , Eritropoyetina/uso terapéutico , Recuperación de Sangre Operatoria/métodos , Anciano , Transfusión de Sangre Autóloga/economía , Transfusión de Sangre Autóloga/instrumentación , Análisis Costo-Beneficio , Método Doble Ciego , Drenaje/economía , Drenaje/instrumentación , Drenaje/métodos , Eritropoyetina/economía , Femenino , Humanos , Masculino , Países Bajos , Oportunidad Relativa , Recuperación de Sangre Operatoria/economía , Recuperación de Sangre Operatoria/instrumentación , Cuidados Posoperatorios/economía , Cuidados Posoperatorios/instrumentación , Cuidados Posoperatorios/métodos , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: Patient blood management is introduced as a new concept that involves the combined use of transfusion alternatives. In elective adult total hip- or knee-replacement surgery patients, the authors conducted a large randomized study on the integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices (DRAIN) to evaluate allogeneic erythrocyte use, while applying a restrictive transfusion threshold. Patients with a preoperative hemoglobin level greater than 13 g/dl were ineligible for erythropoietin and evaluated for the effect of autologous blood reinfusion. METHODS: Patients were randomized between autologous reinfusion by cell saver or DRAIN or no blood salvage device. Primary outcomes were mean intra- and postoperative erythrocyte use and proportion of transfused patients (transfusion rate). Secondary outcome was cost-effectiveness. RESULTS: In 1,759 evaluated total hip- and knee-replacement surgery patients, the mean erythrocyte use was 0.19 (SD, 0.9) erythrocyte units/patient in the autologous group (n = 1,061) and 0.22 (0.9) erythrocyte units/patient in the control group (n = 698) (P = 0.64). The transfusion rate was 7.7% in the autologous group compared with 8.3% in the control group (P = 0.19). No difference in erythrocyte use was found between cell saver and DRAIN groups. Costs were increased by 298 per patient (95% CI, 76 to 520). CONCLUSION: In patients with preoperative hemoglobin levels greater than 13 g/dl, autologous intra- and postoperative blood salvage devices were not effective as transfusion alternatives: use of these devices did not reduce erythrocyte use and increased costs.
Asunto(s)
Artroplastia de Reemplazo de Cadera/métodos , Artroplastia de Reemplazo de Rodilla/métodos , Transfusión Sanguínea/métodos , Procedimientos Quirúrgicos Electivos/métodos , Hemoglobinas/análisis , Recuperación de Sangre Operatoria/métodos , Anciano , Transfusión Sanguínea/economía , Transfusión Sanguínea/estadística & datos numéricos , Transfusión de Sangre Autóloga/economía , Transfusión de Sangre Autóloga/instrumentación , Transfusión de Sangre Autóloga/métodos , Análisis Costo-Beneficio , Método Doble Ciego , Drenaje/economía , Drenaje/instrumentación , Drenaje/métodos , Eritropoyetina/economía , Eritropoyetina/uso terapéutico , Femenino , Humanos , Masculino , Países Bajos , Recuperación de Sangre Operatoria/economía , Recuperación de Sangre Operatoria/instrumentación , Cuidados Posoperatorios/economía , Cuidados Posoperatorios/instrumentación , Cuidados Posoperatorios/métodos , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: It has been suggested that transfusion information from scientific sources (vs. popular sources) is seen as more trustworthy and that interventions should consider using scientific styles. Before such suggestions can be implemented, it is necessary to know if this science source-trust link is observed across different sociodemographic groups and psychological characteristics. A large-scale field-based study examining the importance of sociodemographics and psychological characteristics on the source-trust link was conducted. STUDY DESIGN AND METHODS: A large field-based experiment (the Euro Blood Substitutes Project) was conducted on four different samples (the general public, blood donors, patients, and health experts) in the UK and The Netherlands (total n = 3935). Questions examined levels of trust about sources of transfusion medicine, various aspects of knowledge, and demographic data. RESULTS: People differentiated between scientific and popular sources, with scientific sources perceived as more trustworthy. General trust in transfusion medicine was higher for those who believe that they or scientists were knowledgeable about transfusion medicine or genetic modification (GM). This suggests that people do not differentiate in their subjective knowledge between GM and transfusion medicine. This science trust-source relationship was moderated by a variety of demographic (e.g., younger people were more likely to trust scientific sources) and psychological (e.g., those who rate science as knowledgeable were more trusting of scientific sources) factors. CONCLUSION: The trust-source link is not stable and communications should be targeted to the specific population samples for which they will be most effective; scientifically styled information will be particularly effective for communicating information within certain populations.
Asunto(s)
Transfusión Sanguínea , Alfabetización en Salud , Difusión de la Información , Encuestas y Cuestionarios , Femenino , Humanos , Masculino , Países Bajos , Reino UnidoRESUMEN
BACKGROUND: Total knee replacement (TKR) is increasingly performed in short term hospital stay, making same day mobilization an important issue is after surgery. This implies little joint effusion by reducing intra-articular blood loss, which will enhance knee range of motion. The application of a topical fibrin sealant on the intraoperative bare bone and synovial tissue may contribute to better early full mobilization and thus improved functional outcomes. Since ambulation with a fully extended knee is less strenuous, we hypothesized that patients who received fibrin sealant would demonstrate improved early knee extension after six weeks compared to patients who received standard care. METHODS: A multicenter randomized controlled trial in a consecutive series of osteoarthritis patients scheduled for TKR surgery. Participants were randomized to receive fibrin sealant or not before closing the knee joint capsule. Primary outcome was change in knee extension angle(°) at short term (2 weeks) follow-up (cExt). Secondary outcomes were 6-week extension angle, knee flexion angle, hemoglobin loss, blood transfusion rates, complication rates, the Knee Society Score, and the KOOS and EQ5D questionnaires. RESULTS: When data on primary outcome became available from 250 patients, an interim analysis was performed by an independent Data Safety Monitoring Board for safety and effectivity assessment. This analysis showed that sufficient patients were included to detect a cExt of 10° between both groups. Inclusion was stopped however, all in the meantime included patients were treated according to their randomization. A total of 466 were available for analysis. Both groups were comparable in terms of baseline characteristics. The estimated mean cExt difference was 0.2° (95%CI -0.5 to 0.9). No differences in secondary outcomes were found. CONCLUSIONS: No beneficial effects or side effects were found of a topically applied fibrin sealant during TKR surgery. These results discourage the clinical use of a fibrin sealant in TKR. TRIAL REGISTRATION: Dutch Trial Register, NTR2500.
Asunto(s)
Artroplastia de Reemplazo de Rodilla/métodos , Adhesivo de Tejido de Fibrina/uso terapéutico , Osteoartritis/cirugía , Diseño de Prótesis , Adulto , Anciano , Anciano de 80 o más Años , Pérdida de Sangre Quirúrgica , Transfusión Sanguínea/estadística & datos numéricos , Femenino , Hemostáticos/uso terapéutico , Humanos , Articulación de la Rodilla/cirugía , Masculino , Persona de Mediana Edad , Países Bajos , Hemorragia Posoperatoria/etiología , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
INTRODUCTION: Patients with chemotherapy-induced thrombocytopaenia frequently experience minor and sometimes severe bleeding complications. Unrestrictive availability of safe and effective blood products is presumed by treating physicians as well as patients. Pathogen reduction technology potentially offers the opportunity to enhance safety by reducing bacterial and viral contamination of platelet products along with a potential reduction of alloimmunisation in patients receiving multiple platelet transfusions. METHODS AND ANALYSIS: To test efficacy, a randomised, single-blinded, multicentre controlled trial was designed to evaluate clinical non-inferiority of pathogen-reduced platelet concentrates treated by the Mirasol system, compared with standard plasma-stored platelet concentrates using the percentage of patients with WHO grade ≥ 2 bleeding complications as the primary endpoint. The upper limit of the 95% CI of the non-inferiority margin was chosen to be a ≤ 12.5% increase in this percentage. Bleeding symptoms are actively monitored on a daily basis. The adjudication of the bleeding grade is performed by 3 adjudicators, blinded to the platelet product randomisation as well as by an automated computer algorithm. Interim analyses evaluating bleeding complications as well as serious adverse events are performed after each batch of 60 patients. The study started in 2010 and patients will be enrolled up to a maximum of 618 patients, depending on the results of consecutive interim analyses. A flexible stopping rule was designed allowing stopping for non-inferiority or futility. Besides analysing effects of pathogen reduction on clinical efficacy, the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) is designed to answer several other pending questions and translational issues related to bleeding and alloimmunisation, formulated as secondary and tertiary endpoints. ETHICS AND DISSEMINATION: Ethics approval was obtained in all 3 participating countries. Results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NTR2106; Pre-results.
Asunto(s)
Transfusión de Plaquetas/métodos , Trombocitopenia/terapia , Adolescente , Adulto , Anciano , Infecciones Bacterianas/prevención & control , Patógenos Transmitidos por la Sangre , Protocolos Clínicos , Hemorragia/prevención & control , Humanos , Persona de Mediana Edad , Transfusión de Plaquetas/efectos adversos , Riboflavina/farmacología , Método Simple Ciego , Resultado del Tratamiento , Rayos Ultravioleta , Virosis/prevención & control , Adulto JovenRESUMEN
OBJECTIVES: Anti-inflammatory effects of tranexamic acid and aprotinin, used to abate perioperative blood loss, are reported and might be of substantial clinical relevance. The study of messenger ribonucleic acid synthesis provides a valuable asset in evaluating the inflammatory pathways involved. METHODS: Whole-blood messenger ribonucleic acid expression of 114 inflammatory genes was compared pre- and postoperatively in 35 patients randomized to receive either placebo, tranexamic acid, or aprotinin. These results were further confirmed by reverse transcription-polymerase chain reaction. RESULTS: Of the 23 genes exhibiting independently altered postoperative gene expression levels, 8 were restricted to the aprotinin group only (growth differentiation factor 3, interleukin 19, interleukin 1 family member 7, transforming growth factor α, tumor necrosis factor superfamily 10, tumor necrosis factor superfamily 12, tumor necrosis factor superfamily 13B, vascular endothelial growth factor α), whereas both aprotinin and tranexamic acid altered gene expression of 3 genes as compared with placebo (FMS-related tyrosine kinase 3 ligand, growth differentiation factor 5, interferon-α8). In general, less upregulation of pro-inflammatory, and more upregulation of anti-inflammatory, genes was observed for patients treated with antifibrinolytics. Gene expression affected by aprotinin coded mostly for proteins that function through serine proteases. CONCLUSIONS: This study demonstrates that the use of tranexamic acid and aprotinin results in altered inflammatory pathways on the genomic expression level. We further demonstrate that the use of aprotinin leads to significant attenuation of the immune response, with several inhibitory effects restricted to the use of aprotinin only. The results aid in a better understanding of the targets of these drugs, and add to the discussion on which antifibrinolytic can best be used in the cardiac surgical patient.
Asunto(s)
Antifibrinolíticos/uso terapéutico , Aprotinina/uso terapéutico , Procedimientos Quirúrgicos Cardíacos , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/cirugía , Expresión Génica , Inflamación/genética , ARN Mensajero/sangre , Ácido Tranexámico/uso terapéutico , Anciano , Enfermedades Cardiovasculares/inmunología , Estudios de Casos y Controles , Distribución de Chi-Cuadrado , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Placebos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Estadísticas no Paramétricas , Regulación hacia ArribaRESUMEN
BACKGROUND: The objective was to investigate the use of autologous red blood cells (RBCs) derived from umbilical cord blood (UCB), as an alternative for allogeneic transfusions in premature infants admitted to a tertiary neonatal center. STUDY DESIGN AND METHODS: UCB collection was performed at deliveries of less than 32 weeks of gestation and processed into autologous RBC products. Premature infants requiring a RBC transfusion were randomly assigned to an autologous or allogeneic product. The primary endpoint was an at least 50 percent reduction in allogeneic transfusion needs. RESULTS: Fifty-seven percent of the collections harvested enough volume (> or =15 mL) for processing. After being processed, autologous products (> or =10 mL/kg) were available for 36 percent of the total study population and for 27 percent of the transfused infants and could cover 58 percent (range, 25%-100%) of the transfusion needs within the 21-day product shelf life. Availability of autologous products depended most on the gestational age. Infants born between 24 and 28 weeks had the lowest availability (17%). All products, however, would be useful in view of their high (87%) transfusion needs. Availability was highest (48%) for the infants born between 28 and 30 weeks. For 42 percent of the infants with transfusion needs in this group, autologous products were available. For the infants born between 30 and 32 weeks, autologous products were available for 36 percent of the infants. Transfusion needs in this group were, however, much lower (19%) compared to the other gestational groups. CONCLUSION: Autologous RBCs derived from UCB could not replace 50 percent of allogeneic transfusions due to the low UCB volumes collected and subsequent low product availability.
Asunto(s)
Anemia/terapia , Transfusión de Sangre Autóloga/métodos , Sangre Fetal , Recien Nacido Prematuro , Anemia/sangre , Transfusión de Sangre Autóloga/economía , Volumen Sanguíneo , Transfusión de Eritrocitos/economía , Transfusión de Eritrocitos/métodos , Estudios de Factibilidad , Femenino , Edad Gestacional , Costos de la Atención en Salud , Humanos , Recién Nacido , Embarazo , Resultado del TratamientoRESUMEN
OBJECTIVE: To compare postoperative complications in patients undergoing major surgery who received non-filtered or filtered red blood cell transfusions. DESIGN: Prospective, randomised, double blinded trial. SETTING: 19 hospitals throughout the Netherlands (three university; 10 clinical; six general). PARTICIPANTS: 1051 evaluable patients: 79 patients with ruptured aneurysm, 412 patients undergoing elective surgery for aneurysm, and 560 undergoing gastrointestinal surgery. INTERVENTIONS: The non-filtered products had the buffy coat removed and were plasma reduced. The filtered products had the buffy coat removed, were plasma reduced, and filtered before storage to remove leucocytes. MAIN OUTCOME MEASURES: Mortality and duration of stay in intensive care. Secondary end points were occurrence of multi-organ failure, infections, and length of hospital stay. RESULTS: No significant differences were found in mortality (odds ratio for filtered v non-filtered 0.80, 95% confidence interval 0.53 to 1.21) and in mean stay in intensive care (- 0.4 day, - 1.6 to 0.6 day). In the filtered group the mean length of hospital stay was 2.4 days shorter (- 4.8 to 0.0 day; P = 0.050) and the incidence of multi-organ failure was 30% lower (odds ratio 0.70, 0.49 to 1.00; P = 0.050). There were no differences in rates of infection (0.98, 0.73 to 1.32). CONCLUSION: The use of filtered transfusions in some types of major surgery may reduce the length of hospital stay and the incidence of postoperative multi-organ failure.